JP7301840B2 - Ｌｐａアンタゴニストとしてのイソキサゾールｎ結合カルバモイルシクロヘキシル酸 - Google Patents
Ｌｐａアンタゴニストとしてのイソキサゾールｎ結合カルバモイルシクロヘキシル酸 Download PDFInfo
- Publication number
- JP7301840B2 JP7301840B2 JP2020533679A JP2020533679A JP7301840B2 JP 7301840 B2 JP7301840 B2 JP 7301840B2 JP 2020533679 A JP2020533679 A JP 2020533679A JP 2020533679 A JP2020533679 A JP 2020533679A JP 7301840 B2 JP7301840 B2 JP 7301840B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- amino
- oxy
- carbonyl
- lpa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607407P | 2017-12-19 | 2017-12-19 | |
| US62/607,407 | 2017-12-19 | ||
| PCT/US2018/066128 WO2019126099A1 (en) | 2017-12-19 | 2018-12-18 | Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021507896A JP2021507896A (ja) | 2021-02-25 |
| JP2021507896A5 JP2021507896A5 (https=) | 2022-01-27 |
| JPWO2019126099A5 JPWO2019126099A5 (https=) | 2022-01-27 |
| JP7301840B2 true JP7301840B2 (ja) | 2023-07-03 |
Family
ID=65003584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020533679A Active JP7301840B2 (ja) | 2017-12-19 | 2018-12-18 | Ｌｐａアンタゴニストとしてのイソキサゾールｎ結合カルバモイルシクロヘキシル酸 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11447475B2 (https=) |
| EP (1) | EP3728210B1 (https=) |
| JP (1) | JP7301840B2 (https=) |
| KR (1) | KR102756637B1 (https=) |
| CN (1) | CN112041304B (https=) |
| ES (1) | ES3063964T3 (https=) |
| WO (1) | WO2019126099A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| EP4011875A1 (en) | 2017-12-19 | 2022-06-15 | Bristol-Myers Squibb Company | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| KR102788997B1 (ko) | 2018-09-18 | 2025-03-28 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 옥사비시클로 산 |
| ES2946657T3 (es) | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
| CN111434655A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| KR20220024549A (ko) * | 2019-06-18 | 2022-03-03 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 이속사졸 카르복실산 |
| AU2020384883B2 (en) | 2019-11-15 | 2023-11-16 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof |
| JP2023505704A (ja) | 2019-12-12 | 2023-02-10 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｌｐａ受容体２阻害剤としてのキナゾリン誘導体 |
| WO2021116259A1 (en) | 2019-12-12 | 2021-06-17 | Chiesi Farmaceutici S.P.A. | Aromatic amido derivatives as lpa receptor 2 inhibitors |
| CN114746425A (zh) | 2019-12-12 | 2022-07-12 | 奇斯药制品公司 | 作为lpa受体2抑制剂的噻吩并嘧啶衍生物 |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| CN115867556B (zh) | 2020-06-03 | 2025-05-06 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| WO2022013378A1 (en) | 2020-07-16 | 2022-01-20 | Chiesi Farmaceutici S.P.A. | Amido cyclohexane acid derivatives as lpa receptor inhibitors |
| EP4670791A3 (en) * | 2020-10-22 | 2026-03-04 | Lhotse Bio, Inc. | Compounds and compositions for treating conditions associated with lpa receptor activity |
| CN114456157A (zh) * | 2020-11-10 | 2022-05-10 | 武汉人福创新药物研发中心有限公司 | 氮取代氨基碳酸酯噻吩类化合物及其用途 |
| WO2022174883A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| WO2022174882A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| JP2024512557A (ja) | 2021-03-24 | 2024-03-19 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｌｐａ受容体２阻害物質としての８－シクロ－置換キナゾリン誘導体 |
| TWI853704B (zh) | 2021-05-11 | 2024-08-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| WO2023107938A1 (en) | 2021-12-08 | 2023-06-15 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2023118253A1 (en) | 2021-12-23 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Cyclohexane acid derivatives as lpa receptor inhibitors |
| AR128613A1 (es) | 2022-02-25 | 2024-05-29 | Lhotse Bio Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa |
| EP4490150A1 (en) | 2022-03-08 | 2025-01-15 | Chiesi Farmaceutici S.p.A. | Amido cyclopropyl derivatives as lpa receptor inhibitors |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013501064A (ja) | 2009-08-04 | 2013-01-10 | アミラ ファーマシューティカルス，インコーポレーテッド | リゾホスファチジン酸受容体アンタゴニストとしての化合物 |
| JP2013506680A (ja) | 2009-10-01 | 2013-02-28 | アミラ ファーマシューティカルス，インコーポレーテッド | リゾホスファチジン酸受容体アンタゴニストとしての多環式化合物 |
| WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| JP2016515536A (ja) | 2013-03-15 | 2016-05-30 | エピゲン バイオサイエンシズ, インコーポレイテッドEpigen Biosciences, Inc. | 疾患の治療に有用な複素環化合物 |
| JP2021506863A (ja) | 2017-12-19 | 2021-02-22 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアゾール |
| JP2021507895A (ja) | 2017-12-19 | 2021-02-25 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｐａアンタゴニストとしてのピラゾールｎ−連結のカルバモイルシクロヘキシル酸 |
| JP2021507899A (ja) | 2017-12-19 | 2021-02-25 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｐａアンタゴニストとしてのイソキサゾールｏ−架橋カルバモイルシクロヘキシル酸 |
| JP2021508686A (ja) | 2017-12-19 | 2021-03-11 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｐａアンタゴニストとしてのトリアゾールｎ結合カルバモイルシクロヘキシル酸 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE420878T1 (de) | 2000-02-18 | 2009-01-15 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
| WO2002062389A1 (en) | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| JP4692281B2 (ja) | 2003-08-05 | 2011-06-01 | 味の素株式会社 | 新規アゾール化合物 |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| EA201390821A1 (ru) | 2010-12-07 | 2013-10-30 | Амира Фармасьютикалс, Инк. | Антагонисты рецепторов лизофосфатидной кислоты и их применение |
| US8785442B2 (en) | 2011-01-30 | 2014-07-22 | Curegenix, Inc. | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof |
| EP2694472B1 (en) | 2011-04-05 | 2020-03-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| US20140329871A1 (en) | 2011-12-04 | 2014-11-06 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
| UA109868C2 (ru) | 2012-06-20 | 2015-10-12 | Ф. Хоффманн-Ля Рош Аг | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) |
| SG11201407228PA (en) | 2012-06-20 | 2014-12-30 | Hoffmann La Roche | N-aryltriazole compounds as lpar antagonists |
| JP2017095366A (ja) | 2015-11-18 | 2017-06-01 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
-
2018
- 2018-12-18 US US16/954,550 patent/US11447475B2/en active Active
- 2018-12-18 JP JP2020533679A patent/JP7301840B2/ja active Active
- 2018-12-18 CN CN201880089219.XA patent/CN112041304B/zh active Active
- 2018-12-18 KR KR1020207020557A patent/KR102756637B1/ko active Active
- 2018-12-18 ES ES18830685T patent/ES3063964T3/es active Active
- 2018-12-18 EP EP18830685.6A patent/EP3728210B1/en active Active
- 2018-12-18 WO PCT/US2018/066128 patent/WO2019126099A1/en not_active Ceased
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013501064A (ja) | 2009-08-04 | 2013-01-10 | アミラ ファーマシューティカルス，インコーポレーテッド | リゾホスファチジン酸受容体アンタゴニストとしての化合物 |
| JP2013506680A (ja) | 2009-10-01 | 2013-02-28 | アミラ ファーマシューティカルス，インコーポレーテッド | リゾホスファチジン酸受容体アンタゴニストとしての多環式化合物 |
| WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| JP2016515536A (ja) | 2013-03-15 | 2016-05-30 | エピゲン バイオサイエンシズ, インコーポレイテッドEpigen Biosciences, Inc. | 疾患の治療に有用な複素環化合物 |
| JP2021506863A (ja) | 2017-12-19 | 2021-02-22 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアゾール |
| JP2021507895A (ja) | 2017-12-19 | 2021-02-25 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｐａアンタゴニストとしてのピラゾールｎ−連結のカルバモイルシクロヘキシル酸 |
| JP2021507899A (ja) | 2017-12-19 | 2021-02-25 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｐａアンタゴニストとしてのイソキサゾールｏ−架橋カルバモイルシクロヘキシル酸 |
| JP2021508686A (ja) | 2017-12-19 | 2021-03-11 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｐａアンタゴニストとしてのトリアゾールｎ結合カルバモイルシクロヘキシル酸 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019126099A1 (en) | 2019-06-27 |
| EP3728210C0 (en) | 2026-02-11 |
| CN112041304A (zh) | 2020-12-04 |
| EP3728210B1 (en) | 2026-02-11 |
| KR20200100724A (ko) | 2020-08-26 |
| ES3063964T3 (en) | 2026-04-21 |
| CN112041304B (zh) | 2025-03-07 |
| US20200308157A1 (en) | 2020-10-01 |
| JP2021507896A (ja) | 2021-02-25 |
| KR102756637B1 (ko) | 2025-01-16 |
| US11447475B2 (en) | 2022-09-20 |
| EP3728210A1 (en) | 2020-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7301840B2 (ja) | Ｌｐａアンタゴニストとしてのイソキサゾールｎ結合カルバモイルシクロヘキシル酸 | |
| JP7256807B2 (ja) | Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアゾール | |
| JP7301839B2 (ja) | Ｌｐａアンタゴニストとしてのピラゾールｎ－連結のカルバモイルシクロヘキシル酸 | |
| JP7274486B2 (ja) | Ｌｐａアンタゴニストとしてのトリアゾールｎ結合カルバモイルシクロヘキシル酸 | |
| JP7202383B2 (ja) | Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸 | |
| JP7526096B2 (ja) | Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン | |
| JP7369125B2 (ja) | Ｌｐａアンタゴニストとしてのイソキサゾールｏ－架橋カルバモイルシクロヘキシル酸 | |
| JP7427658B2 (ja) | Ｌｐａアンタゴニストとしてのシクロペンチル酸 | |
| JP7280881B2 (ja) | Ｌｐａアンタゴニストとしてのシクロヘキシル酸トリアゾールアゾール | |
| JP7299892B2 (ja) | Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン | |
| JP7465899B2 (ja) | Ｌｐａアンタゴニストとしてのシクロブチルカルボン酸 | |
| JP7212047B2 (ja) | Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール | |
| JP7465898B2 (ja) | Ｌｐａアンタゴニストとしてのトリアゾールカルボン酸 | |
| KR102800284B1 (ko) | Lpa 길항제로서의 시클로헵틸 산 | |
| JP7412424B2 (ja) | Ｌｐａアンタゴニストとしてのオキサビシクロ酸 | |
| JP7422788B2 (ja) | Ｌｐａアンタゴニストとしてのイソキサゾールカルボン酸 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220119 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221110 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230313 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230613 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230621 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7301840 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |